Superpower peptides available for pre-order. Get first access.
Not FDA-approved
Hormones & metabolism
What are the side effects of MOTS-c?
MOTS-c has no established human side-effect profile yet. See what FDA's adverse-event search found, product checks, and when to call a clinician.
Quick answer
MOTS-c is not FDA-approved, has no established labeled route, and has no established human side-effect profile. Research on giving MOTS-c comes from cells and rodents. The nearest completed human trial tested a modified analog in 88 people. FDA's adverse-event searches through March 2025 found no MOTS-c reports, which does not establish safety. Spreading redness or fever near an injection site warrants calling the prescribing clinician; wheezing or facial swelling needs emergency care. WADA prohibits MOTS-c at all times.
- Published
- November 4, 2026
- Last updated
- November 4, 2026
Where MOTS-c safety research stands
FDA identified no clinical studies or human exposure data1 for MOTS-c by any route. It therefore considers potential safety risks in people unknown. Published studies of giving MOTS-c come from cell and rodent models1. MOTS-c is a 16-amino-acid mitochondrial-derived peptide2 that the body makes naturally.
What MOTS-c side effects have been reported?
FDA's adverse-event searches through March 9, 2025, retrieved no MOTS-c reports1. Pharmacies that compound individual prescriptions generally do not report adverse events1. Unless someone reports a reaction, FDA may not be aware of it.
What do studies show about MOTS-c safety?
MOTS-c earned its metabolic reputation in mice, where it reduced diet-induced insulin resistance and obesity2. A 2026 review describes MOTS-c data as almost entirely preclinical, with no major signs of toxicity3. FDA did not identify standard animal toxicity studies1. These findings describe animal research rather than a human safety profile.
The nearest human research tested CB4211, a modified analog of MOTS-c4, injected under the skin. That 88-person Phase 1 trial5 enrolled healthy adults and people with fatty liver disease. It was completed in April 2021 and has not posted results. As a different molecule, CB4211 describes the analog rather than MOTS-c itself.
Research material may also differ from the MOTS-c product a person actually receives.
MOTS-c product quality and safety
The product itself is part of MOTS-c safety. FDA judged compounding-grade MOTS-c not well characterized1.
- Immune reactions: Peptides can trigger immune responses ranging from symptom-free antibodies to life-threatening reactions1.
- Impurities: Clumping and peptide-related impurities cannot be ruled out1 in hard-to-characterize compounded MOTS-c6.
- Sterility: For injected MOTS-c, sterility, bacterial toxins, and particles are critical safety factors1.
- Identity: Inconsistent MOTS-c naming means a patient may receive a different substance1 than ordered.
- Storage: Freeze-dried MOTS-c is expected to stay stable when stored below -4°F (-20°C)1, dry, and away from light.
A reaction could trace to the product, the injection, or MOTS-c itself, so its warning signs are worth knowing.
How can MOTS-c side effects be managed?
Any new symptom after MOTS-c warrants a prompt call to the prescribing clinician, while a severe allergic reaction needs an emergency call to 9117.
- Watch the injection site: A skin infection brings pain, spreading redness, warm skin, and fever with chills8.
- Write it down: Symptom timing, duration, and other medicines help the clinician judge a reaction.
- Contact the clinician: Infection signs warrant contact right away8. So do shaking, sweating, and other low-blood-sugar signs9 in someone on diabetes medicines. Reactions can also be reported to FDA's MedWatch program10.
- Get emergency care: Wheezing; chest tightness; or swelling of the face, eyes, or tongue, with or without hives, can appear within minutes7 and need 911.
Some MOTS-c risks are easier to weigh before a first dose.
Who should talk to a clinician first?
Some health factors call for a review with the prescribing clinician before starting MOTS-c. Each reason comes from a mouse finding or open research question, not harm in people.
| Before using MOTS-c, discuss | Why it matters |
| Diabetes, prediabetes, or glucose-lowering medicines | Mice given MOTS-c needed about 30% more infused glucose2 to hold normal blood sugar during an insulin test, and blood glucose fell by about 50%1 in diet-induced obese mice; blood-sugar effects call for individual review |
| Pregnancy or breastfeeding | No developmental or reproductive toxicity studies1 of MOTS-c identified, so reproductive safety in people is not established |
| Long-term use or a history of cancer | No repeat-dose or cancer-risk studies1 identified, so long-term use and cancer history call for individual review |
| Heart, kidney, liver, or other chronic conditions, and other medicines | MOTS-c's molecular targets and in-body handling remain unknown1, so the organs it could affect are hard to predict |
For competitive athletes, sport rules add a separate question that health history cannot answer.
WADA prohibits MOTS-c at all times11 as an activator of AMPK, an energy-sensing enzyme, under class S4.4.1 of its 2026 Prohibited List. Athletes subject to drug testing can face sanctions and should check current WADA and league rules.
Getting MOTS-c in 2026
Superpower will offer MOTS-c formulated in FDA-registered facilities in the US, backed by third-party lab testing, and distributed from US-licensed pharmacies. A licensed clinician will review each person's health history to decide whether MOTS-c fits their health care. The Superpower peptide waitlist is open now.
MOTS-c is not FDA-approved as a drug. It is one of six peptides12 under an interim policy the Department of Health and Human Services announced in October 2026: HHS does not intend to take enforcement action13 against state-licensed pharmacies compounding them while the 503A Bulks List, the roster of ingredients pharmacies may use in compounding, is finalized. Conditions include ingredients from FDA-registered facilities and a patient-specific prescription. The policy came after a July 2026 FDA advisory committee recommendation to add MOTS-c to the list14, and rulemaking on that list continues.